Moneycontrol PRO
Upcoming Webinar:Watch Kushal Bhagi of Tortuga Wealth Managers decode how you can maximise your MF investments on Sept 21 @11am. Register Now

Bharat Biotech's US partner for Covaxin, Ocugen, faces class action lawsuit

Pomerantz alleges in the class action lawsuit that, the defendants (Ocugen) have made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

July 22, 2021 / 01:09 PM IST
A file image of Covaxin.

A file image of Covaxin.

US-based law firm Pomerantz on July 19 announced that it had filed a class action lawsuit against Bharat Biotech's US partner which has licence to develop and distribute Covaxin in US and Canada citing certain violations of the US federal securities laws.

Pomerantz alleges in the class action lawsuit that, the defendants (Ocugen) have made materially false and misleading statements regarding the company's business, operations, and compliance policies.

The class action was filed in the US District Court for the Eastern District of Pennsylvania, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Ocugen securities between February 2, 2021, and June 10, 2021.

"... failed to disclose that the information submitted to the (US)FDA was insufficient to support an EUA, Ocugen would not file an Emergency Use Authorization with the FDA, (and) as a result of the foregoing, the Company's financial statements, as well as defendants' statements about Ocugen's business, operations, and prospects, were false and misleading or lacked a reasonable basis," Pomerantz alleged in its law suit.

On February 2, Ocugen announced an exclusive licensing agreement with Bharat Biotech to obtain exclusive rights to develop, manufacture and commercialise the latter's COVID-19 vaccine Covaxin in the US.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Pomerantz said based on this news, the Ocugen's share price rose from a close of $1.81 per share on February 1, to close at $3.26 per share on February 2, 2021, an increase of approximately 80.1 percent.

"On February 5, submitted investor presentation that described in great detail the Covaxin vaccine characteristics, the "unmet need in the United States" and Ocugen's plan to develop and file an Emergency Use Authorization ("EUA") with the U.S. Food and Drug Administration ("FDA")," Pomerantz said.

"On June 10, 2021, Ocugen issued a press release announcing that it would pursue a "biologics license application" with the FDA instead of the previously announced EUA," it added.

Pomerantz said on the release of the news, the company's share price declined from $9.31 per share of Ocugen stock on June 9, 2021, to close at $6.69 per share on June 10, 2021, a drop of approximately 28.14 percent.
Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: Jul 19, 2021 07:53 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark